Peptides used in the context of hair loss represent a broad area of scientific research, rather than a single standardized method of treatment. This term can refer to precisely defined short sequences of amino acids, copper-binding peptide complexes, protein hydrolysates, or multi-component formulations containing peptides along with plant extracts and other compounds.
These materials may differ significantly in their molecular structure, proposed mechanism of action, mode of delivery to the scalp and hair follicles, formulation, and the level of available clinical evidence.
This distinction is important because the mere presence of the word „peptide” does not mean that two experimental products or materials should behave in the same way.
Some compounds related to peptides have been studied primarily in cell cultures or on isolated human hair follicles. A smaller number of topical preparations have been evaluated in controlled or preliminary studies involving humans.
Positive results obtained at one of these experimental levels can provide valuable information, but they do not prove that any serum containing peptides increases hair density, works in the case of various causes of hair loss, or has an acceptable long-term safety profile.
A thorough review of the evidence should therefore answer several related questions. What type of hair loss was actually studied? What exactly peptide or ready-made formulation was used? What changed compared to the control group? How large was this difference? How long were the participants observed for?
These questions provide much more information than the general question: „do peptides work on hair loss?”.
In this article we use this approach to analyze selected primary studies and explain what stronger clinical evidence would be required before broad claims regarding peptide products used in the context of hair loss could be justified.
Hair loss and its fragility
Similar appearance can have various causes
Visible thinning of the hair can result from several different processes.
In a specific area of the scalp, less visible hair may be present. The individual strands may become thinner. More hair may enter the shedding phase. Existing fibers may also break before reaching their previous length.
In some cases, several such processes may occur simultaneously.
Hair fragility refers to the physical damage to the stem.
The loss involves the shedding of hair from the hair follicles.
Hair density, on the other hand, usually refers to the number of hairs present on a specific area of the scalp.
All these parameters affect the appearance of the hairstyle, but biologically they are not the same thing.
Neither the photograph nor the number of hairs on the brush alone does not allow us to unequivocally determine which process is responsible for the observed change.
For example, a product that reduces brittleness can allow existing hair to retain more length and make the hairstyle look fuller without any change in the activity of the hair follicles.
In turn, an intervention affecting the hair cycle can alter the functioning of the hair without repairing the existing damage along the stem.
Therefore, a statement such as „reduces hair loss” requires additional explanation. Did the study count the hair that fell out from the follicles? Was broken fragments measured? Were the hair counted on a specific area of the scalp? Was the diameter of the hair measured? Were standardized photographs used?
Without information about what exactly was measured, such a term has limited scientific value.
The clinical evaluation of hair loss may include an interview, the condition of the scalp, the characteristics of the hair, and other relevant observations. The American Academy of Dermatology also notes that various causes may overlap, and in some situations additional testing may be necessary.[1]
This is one of the reasons why choosing a product based solely on the list of ingredients does not replace determining the cause of unexplained or ongoing hair loss.
Why terminology can change a scientific conclusion?
A good example is the term „growing out your hair”.
It can mean that a previously poorly visible hair becomes more noticeable. It can also mean that the existing hair begins to produce a visible hair shaft again. In less precise language, the term can simply be used to describe an improvement in the coverage of the scalp.
None of these definitions automatically means the creation of completely new hair follicles.
Similarly, the term „thick hair” can have several meanings.
It can refer to an increase in the diameter of individual strands. It can mean a greater proportion of terminal or thicker hair compared to fine hair. In the cosmetic language, however, it can only mean that the hairstyle looks fuller.
A well-described study should therefore clearly indicate what has been measured.
Improving one parameter can be significant, while another remains unchanged.
A useful question is:
Could the described result have occurred without increasing the number of hairs?
If the answer is „yes”, the result should not automatically be presented as an increase in hair density, unless the density was actually measured.
Peptide research may address different levels of hair biology
Research related to peptides ranges from experiments on extracted hair fibers to controlled clinical trials in humans.
Each experimental level answers a different question.
The studies on the fibers collected primarily concern conditioning and structural and mechanical properties.
Cell culture allows us to test whether a peptide affects specific signaling pathways or cell behavior under controlled laboratory conditions.
Isolated hair follicles constitute a more complex biological system and allow the study of hair follicle responses outside the full environment of the human scalp.
Clinical studies in humans, however, answer the most direct question: does a specific intervention cause a measurable change when it is actually applied by humans?.
For example, AHK-Cu was studied in skin cell cultures and on isolated human hair follicles. The researchers described its effects on, among other things, cell proliferation and the elongation of the hair shaft.[2]
These observations are scientifically important because the cells of the skin’s epidermis and the hair follicles are directly related to the biology of hair.
However, these were laboratory and ex vivo observations.
This was not a controlled clinical study showing that serum available on the market increases hair density in humans.
The exact identity of the molecule is also important. AHK-Cu should not be considered a substitute for GHK-Cu, which has a different sequence.[2]
Both compounds can be referred to broadly as „copper peptides,” but similar terminology does not imply identical compounds or an identical level of evidence.
The distinction between „human tissue research” and „human activity research” is extremely important throughout the literature on peptides.
The hair loss may be caused by a human being, and the experiment may still not answer the question of clinical effectiveness.
Hair density and measurement of hair loss
Density measurement requires a repeatable reference area
Hair density is usually expressed as the number of hairs per certain area of the scalp.
For the result to be reliable, researchers must repeatedly locate the same area, use consistent imaging methods, and clearly specify which hair is being counted.
Otherwise, differences in the position of the camera, the way the frame is composed, the magnification, or the visibility of the hair can create the impression of a biological change.
If the hypothesis includes categories of hair diameter, the study should distinguish the total number of hairs from the number or proportion of hairs belonging to specific categories of diameter.
The output values are also important.
A percentage change without information about the initial value can make the result seem more important than it actually is.
The same principle applies to the comparative group.
Let us imagine, purely for illustrative purposes, that the number of hairs in the assessed area increased within the study group from 100 to 110. This would mean a 10 percent increase within the group.
However, if at the same time the number of hairs increased in the control group as well, the difference that could reasonably be attributed to the intervention under study would be less than 10%.
This is not the result of any peptide study. The example only shows why baseline values and changes in the comparison group should be taken into account when interpreting the results.
The distribution of hair diameter is not the same as the total density
A instructive example is provided by a randomized double-blind study involving 22 Japanese men with androgenic alopecia.
The participants used a lotion containing GPIGS for four months or a control lotion. In the peptide group, there was a greater change in the proportion of thick hair and a smaller proportion of very thin hair, as well as a favorable photographic assessment. [3]
This is an important early clinical sign.
The main quantitative result, however, concerned the distribution of hair diameters.
It should not be presented as evidence of the formation of new hair follicles.
The small sample size of the study, the defined male population, the specific formulation, and the selected endpoints also limit the possibility of generalizing the results.
The study does not automatically show how women would respond.
It does not confirm its effectiveness in other causes of hair loss.
It does not prove that another peptide sequence would yield the same result.
It also does not prove that a shampoo unrelated to this study that contains the word „peptide” on the label would reproduce the observed effect.
The correct interpretation is narrower, but scientifically more powerful: a specific lotion containing GPIGS caused measurable changes in selected hair characteristics in a small controlled study of men with androgenic alopecia.
In the case of products intended for rinsing, completely different exposure conditions must be taken into account. This issue is discussed in more detail in the article. Peptide shampoo: hair conditioning and claims regarding growth.
Hair loss measurement is a separate methodological problem
The measurement of fall requires its own methodology.
The study should determine the method of collecting the hair, the timing of its collection, and whether the frequency of washing and other elements of the routine were standardized.
Researchers may also need to distinguish not only the number of hairs collected but also their characteristics, such as diameter.
Otherwise, differences in the completeness of sampling or in daily grooming habits can affect the result.
In a primary study involving 176 participants, an improved washing test was evaluated in individuals with androgenic alopecia, telogenic alopecia, and without a diagnosed hair loss disorder. [4]
The number and characteristics of the hair that fell out differed between the groups.
This was not a study of peptide therapy.
Its significance is methodological.
It shows that the characteristics of the falling hair can provide important information and that counting everything that is noticed during washing alone does not answer the same question as measuring the density of the hair on the scalp.
The reduction in hair loss does not automatically mean a permanent increase in the number of visible terminal hair.
If the declaration concerns an increase in density, the density must be measured separately.
The participants' experiences are important, but they do not replace objective measurements.
Clinical trials should not ignore what participants actually notice.
For people, it is important whether the scalp becomes less visible, whether the hair is easier to manage, whether fewer hair falls out and whether the change is meaningful in everyday life.
The results reported by the participants can therefore provide valuable information, especially if the questionnaires and assessment methods were defined before the study began and used in a consistent manner.
However, expectations can influence subjective assessments.
An open-label study in which every participant knows that they are receiving a new intervention is more susceptible to the influence of expectations than a reliable study with a blinded comparison group.
The participants' satisfaction should therefore complement objective measurements, and not constitute the sole evidence of hair regrowth.
Population studied and diagnosis
„Hair loss” is not a complete description of the study population.
The study on androgenic alopecia answers a different clinical question than the study on plaque alopecia.
Telogenal hair loss, hair loss associated with chronic stress, and disorders accompanied by scarring also have different mechanisms.
They cannot be treated as one condition just because they all can cause visible hair thinning.
The American Academy of Dermatology describes many different causes of hair loss and emphasizes the importance of proper diagnosis.[5]
In the studies of peptides, this means that it is necessary to explain how the diagnosis was established, what the degree of progression was, how long the problem had been present, and whether another cause could have co-existed.
The claim that one peptide product works on „all types of hair loss” would require a much broader evidence base than a study involving people with a single, strictly defined diagnosis.
Even within the same diagnosis, the response may vary depending on the stage of the disease and the individual characteristics of the participants.
Gender, age, and baseline severity of the problem influence the possibility of generalizing the results.
The results obtained in a small group of adult men cannot be automatically applied to women.
Moreover, it cannot be assumed that children will respond in the same way based on this data.
Similarly, an intervention that causes a measurable change in people with mild hair loss does not necessarily have the same effect in the case of advanced hair loss.
Mixed populations also do not always provide more information.
If the sample size is very small, combining different genders, age groups, or severity levels may result in too few people remaining in individual subgroups to reliably assess the differences.
Publications should therefore accurately describe who was included in the study, who completed the observation, and whether the results were relatively consistent or mainly due to a high response rate from a small number of participants.
These details are important even when the proposed molecular mechanism appears to be relevant in different populations.
The common cellular pathway does not eliminate differences in the biology of the disease, exposure to the formulation, initial severity, or co-existing causes of hair loss.
Preclinical mechanisms are the starting point, not the clinical conclusion
Mechanistic studies can suggest promising hypotheses.
However, they should not be confused with research on treatment in humans.
Pentapeptide P5 with the sequence GLYYF was studied in the context of the activation of the adiponectin receptor 1. The publication included experiments on signaling pathways, studies of isolated follicles, and studies of hair growth in mice. [6]
This provides several levels of preclinical evidence.
However, it does not confirm its effectiveness in a controlled study in humans.
Similarly, in a 2026 study on hydrolyzed keratin, oral exposure was analyzed in mice and experiments were conducted in cell cultures.[7]
The results may contribute to a better understanding of potential biological mechanisms.
However, they should not be used as evidence that a locally applied shampoo or serum will have the same effect in humans.
Cellular results, studies of isolated tissues, animal studies, and human studies should be presented as separate levels of evidence.
Consistency of results at several levels can increase the biological reliability of the hypothesis.
However, it does not replace the missing controlled clinical comparison.
Comparative groups, observation time, and simultaneous interventions
What do controlled studies in humans contribute?
In a 24-week randomized, double-blind study, 32 people with androgenic alopecia participated. The preparation containing acetyltetrapeptide-3, biochanin A, and ginseng extracts was compared with a solution of minoxidil. [8]
In both groups, the number of terminal hairs increased, and the difference between the groups was not statistically significant.
This result justifies further research into this particular mixture.
However, it cannot be concluded that acetylotetrapeptide-3 was responsible for the observed change, as the formulation under investigation also contained other active ingredients.
The absence of a statistically significant difference between the groups also does not automatically mean that the interventions are equivalent.
„No statistically significant difference” and „proven equivalence” are not the same conclusion.
The formal demonstration of equivalence or non-inferiority requires a properly designed study, a previously justified boundary, and sufficiently precise estimates.
In another controlled publication, the cosmetic product containing biomimetic peptides was evaluated in people with plaque psoriasis. During three months of use and during additional observation, the scale for evaluating hair loss on the scalp was used. [9]
The abstract highlights the improvement compared to the initial values.
However, without full comparative results and an accurate assessment of the entire study, such a summary should not be expanded into a strong claim about the superiority of the product or its established therapeutic position.
Studies with a baseline, an active comparator, and additional therapy address different questions
The clinical trial design determines which question can be answered reliably.
A controlled study under controlled conditions allows determining whether the tested formulation produces a greater effect than its base.
The study with an active comparator allows the comparison of the effects of two complete interventions.
The add-on type study allows assessing whether adding a specific intervention to an existing scheme produces an additional effect.
If researchers want to isolate the contribution of a single peptide, the formulated products should ideally differ primarily by the presence of that peptide, while the other components should be appropriately matched.
If several components are changed simultaneously, the positive scientific result applies to the entire combination, and not automatically to just one selected component.
| Research project | What question can he answer? | Important limitation |
|---|---|---|
| Peptide formulation vs adapted substrate | Does the formulation provide an additional effect beyond the action of the base itself? | It does not confirm the activity of all other formulations containing this peptide |
| Mixture vs active comparator | How do the two interventions under study compare with each other? | It may not allow for the determination of the contribution of individual components or the confirmation of equivalence |
| Standard intervention + peptide vs standard intervention + substrate | Does adding a peptide give an additional effect? | The results relate to the specific basic study regimen being examined. |
| Comparison before and after without a control group | Have the measurements changed during use of the product? | It does not allow for a reliable separation of the product's actions from other changes |
This distinction is particularly important for commercial products, as they often contain several ingredients that are advertised in connection with hair condition.
If the mixture yields a favorable result, it can support the evaluation of the finished formulation.
However, it should not be automatically presented as evidence that each of its components would independently produce the same effect.
The observation period should correspond to the declaration
The study, which lasted several months, provides information about what happened during that period.
It is not an investigation covering the entire life.
It may be that little is said about whether the effect persists after use ends, whether the improvement plateau over time, or whether rare side effects appear after much longer exposure.
The assessment of durability therefore requires an appropriate period of observation.
Researchers should document whether participants continued the intervention, ended its use, started another therapy, or changed their routine during the period being evaluated.
The study cannot show that the effect persists after discontinuation of use if all participants use the product until the final measurement.
The absence of long-term observation does not invalidate the true short-term result.
It only limits the request to the time and conditions that were actually observed.
At the same time, the products and interventions used require transparent reporting.
Research on hair loss becomes difficult to interpret if participants simultaneously change several elements of their routine.
If someone starts another therapy, adds a supplement, undergoes a procedure, or abandons harmful beauty practices at the same time as starting to use a peptide product, the improvement cannot be automatically attributed to the peptide.
Standard primary therapy can be scientifically acceptable if both groups receive comparable care, and the study was designed to assess an additional effect.
Observance of the protocol is also important.
It is not possible to properly assess the intervention without knowing whether the participants actually applied it in accordance with the research assumptions.
Missing data and withdrawal from participation are equally important.
An analysis limited solely to participants who willingly used the product and completed all visits may sometimes present a more favorable picture than an analysis that adequately includes all randomly assigned participants.
Reasons for resignation — including irritation, inconvenience, or a lack of noticeable improvement — are part of the evidence.
They should not disappear from interpretations.
Gaps in the evidence regarding peptides and hair loss
Literature is much more diverse than marketing might suggest
The available literature on peptides and hair includes mechanistic cell experiments, studies of isolated follicles, animal models, small-scale studies of specific lotions, and clinical studies of multi-ingredient formulations.
They should not be treated as interchangeable evidence confirming one universal „effect of peptides on hair growth”.
The most important gaps include the lack of independent replication of results, a correspondingly large number of clinical studies, detailed reporting of results for control groups, the characteristics of the delivery of ingredients from specific formulations, and longer follow-up periods.
Independent confirmation is particularly important when a large part of the evidence regarding a particular formulation comes from one research team or is related to one commercial product.
Negative and ambiguous results also have scientific value.
A well-conducted study that does not confirm an attractive laboratory hypothesis helps prevent the presentation of early mechanistic results as inevitable clinical success.
The word „peptide” is not evidence of safety
The mere term „peptide” does not confirm safety.
A small clinical study in which no problems related to the product were reported cannot rule out rare adverse reactions or confirm safety for every population.
The significance is given by the specific molecule, formulation, route of exposure, concentration and duration of use.
Evidence regarding the local cosmetic product cannot also confirm the safety of the peptide administered in a different way simply because both products belong to a broad category of peptides.
Similarly, demonstrating biological activity in cell culture does not mean that increasing exposure in humans would be appropriate.
The evidence examined here concerns the interpretation of research findings and scientific claims.
They do not constitute a protocol for the use of peptides.
What would a stronger set of evidence look like?
A convincing set of clinical evidence should clearly identify both the peptide material under study and the finished formulation.
The clinical question and the primary endpoint are best determined before the study begins.
Researchers should clearly define the population and the recognition, apply appropriate randomization, blinding, and a control group.
The results should include absolute initial and final values, and not merely favorably looking percentage values.
The results of the control group should be presented alongside the changes in the studied group.
Uncertainty regarding the estimated effects should be reported.
Adverse effects, resignations and missing data should be presented clearly.
The observation period should be long enough to justify the declaration regarding the durability of the effect.
Equally important, the entire body of evidence should distinguish between the apparent clinical improvement and the proposed molecular mechanism.
A clinical study may show a repeatable improvement without proving every biological step responsible for this effect.
On the other hand, even a very convincing molecular mechanism does not confirm the clinical regrowth of hair if the corresponding clinical effect has never been demonstrated.
Frequently asked questions
Can „before and after” photos confirm hair regrowth?
Before-and-after photos can document a change in appearance, but uncontrolled photographs in themselves do not prove that the peptide caused the hair regrowth. Lighting, the way the clip is applied, the length of the hair, the styling, the camera angle, the distance and position of the scalp can all influence the visible coverage. In the GPIGS study, however, the blinded photographic assessment was combined with measurements related to hair diameter, rather than relying solely on standard photographs. [3] Stronger clinical evidence combines standardized photography with repeatable quantitative measurements and an appropriate control group.
Can the results regarding one type of hair loss be transferred to another?
No. Different diagnoses can encompass different biological processes, clinical course, and response to intervention. In the selected literature, studies regarding androgenic alopecia and seborrheic alopecia include separate populations. [8][9] The results should remain related to the population and the intervention that was actually studied. A result in androgenic alopecia does not automatically confirm efficacy in patch-like, telogenic, tractional, or scarring alopecia.
Do peptides constitute a standardized method of action in the case of hair loss?
No. The peptide terminology encompasses many different molecules and mixtures with different structures, formulations, and research histories. The AHK-Cu laboratory studies, the GPIGS lotion clinical study, and the multicomponent formulation containing acetyltetrapeptide-3 do not involve the same intervention. [2][3][8] Combining these studies may be useful in describing the entire field, but it does not allow determining a single expected clinical effect or a single safety profile.
Does the reduction in hair loss guarantee an increase in hair density?
No. Hair loss refers to the shedding of hair, whereas density refers to the number of hairs present on a specific area of the scalp. In the improved washing test, both the number and characteristics of the shedding hair were analyzed, showing that the hair loss itself is more complex than a single numerical result.[4] If the product is intended to increase density, the test should measure the density directly.
Do thicker hair mean more hair?
No. Existing strands can increase diameter without simultaneously increasing the number of hairs. The results of the GPIGS study on changes in the proportion of thicker and thinner hairs show why the diameter distribution should not be presented as the formation of new follicles. [3] Both diameter and the number of hairs can affect the visibility of the scalp, but these are different parameters with different biological significance.
Does the experiment on human hair follicles prove that the serum works in humans?
No. Isolated human hair follicles are subjected to exposure in controlled laboratory conditions outside the full scalp environment. This does not replicate the delivery of substances, metabolism, repeated application, and actual conditions of product use. AHK-Cu studies included observations of the follicles ex vivo. [2] They provide information about the biological reliability of the mechanism, but do not determine the magnitude, repeatability, or durability of the clinical effect in humans.
Are all copper peptides interchangeable in hair studies?
No. The peptide sequence and its copper complex are part of the identity of the material under study. The cited study of the stem cells concerned AHK-Cu and should not be presented as a clinical study of GHK-Cu. [2] A similar name or common copper ion does not imply the same mode of delivery, molecular interactions, or biological effects.
Does a positive test result in mice predict hair regrowth in humans?
No. A positive study in mice can provide scientific justification for further research, but it does not allow for a reliable prediction of clinical efficacy in humans. The P5 studies included experiments on the hair cycle in mice, whereas the hydrolized keratin studies also used mice, but in a different exposure model.[6][7] Species differences, route of administration, formulation, and biological context can influence the response.
Does „no significant difference compared to minoxidil” mean the same effectiveness?
No. The absence of a statistically significant difference does not prove equivalence of two interventions. In a small study involving a combination containing acetyltetrapeptide-3, no statistically significant difference was found between the groups, but that alone does not confirm equivalence. [8] Equivalence and non-inferiority studies require an appropriate design, pre-specified boundaries, and sufficiently precise confidence intervals.
Does the testing of a multi-peptide or multi-component serum allow determining which peptide is responsible for the result?
Usually not, if the entire mixture is tested as a single intervention. A positive result may support the evaluation of the finished formulation, but does not allow determining the contribution of each component. The clinical study of acetyltetrapeptide-3 also included plant components. [8] To more accurately isolate the contribution of the individual components, appropriately matched comparisons or another design allowing their separation would be needed.
How long should the peptide study be conducted in the context of hair loss?
There is no one time that is appropriate for every question. Selected clinical trials include periods of use lasting several months, and some also include additional observation. [3][9] The appropriate time depends on the diagnosis, the endpoint being examined, and the type of declaration. The study may show an early measurable change, but at the same time it does not provide information on whether the effect persists after discontinuation.
Can it be assumed that women will respond the same way as men?
No. A study that only included men provides direct data about the population that was actually examined. The GPIGS study included men, whereas the multivariable formulation study included both men and women.[3][8] These differences should remain visible in the summary of the evidence. A small mixed study may also be too small to reliably assess the response separately in women and men.
Do peptide products treat scarring alopecia?
Selected evidence does not support this claim. Results obtained in a specific non-neoplastic condition cannot prove the reversal of another disease process involving a different hair follicle pathology. The causes of hair loss require clinical differentiation.[5] The presence of peptides on the product label does not replace evidence related to a specific diagnosis.
Does the lack of reported adverse reactions prove the safety of the peptide product?
No. Small or short-term studies may not detect rare adverse reactions and may exclude individuals with certain risk factors. Beneficial observation of tolerance to a single lot is primarily related to that formulation, the population studied, and the length of observation. [3] The safety interpretation should take into account the manner of collecting information on adverse reactions, participant attrition, and the availability of data from a longer period.
Can the improvement be attributed to the peptide serum if another intervention is also being used at the same time?
Only when the study design allows for the addition of serum properly separated from the main treatment can the additional effect of the serum be investigated. If both groups receive the same primary therapy and one group additionally receives a peptide serum while the other receives a matched substrate, the additional effect of the serum can be investigated. However, when comparing a mixture with another active intervention, both complete regimens are evaluated. [8] If several elements change simultaneously without an appropriate control group, improvements cannot be reliably attributed to the peptide itself.
Are consumer opinions evidence that the peptide causes hair growth?
Consumer opinions can describe individual experiences and help formulate research questions, but they do not provide a controlled assessment of clinical effectiveness. Opinion authors may have different causes of hair loss, use different products or interventions, differ in the severity of the problem, the conditions under which the images are taken, and the time between observations. Research on hair loss shows that seemingly similar problems can affect very different populations. [4] Opinions should therefore be kept separate from controlled clinical measurements.
What information should a reliable statement regarding peptides and hair loss contain?
It should indicate the exact peptide or finished product, the identification, number and characteristics of the participants, the comparator group, the endpoint measured, the time of the study, and the uncertainty of the result. It should also inform whether the evidence comes from clinical studies in humans, isolated human tissues, animal studies, or cell culture, because the literature on peptides covers all these levels of evidence. [2][6][8] An attractive mechanism, a single laboratory result, or a convincing image do not replace the missing clinical comparison.
Summary
Research on peptides in the context of hair loss includes reliable scientific questions, mechanistic findings, and some early clinical signals in humans. However, the available evidence does not confirm the existence of a single broad class of effective „peptide methods for hair loss.”.
The most justified interpretation preserves each result in the context of the exact relationship, the ready-made formulation, the recognition, the population, the comparison group, the endpoint, and the observation time.
This is particularly important because seemingly similar results can reflect completely different biological processes.
The limitation of fragility concerns the preservation of existing fibers.
The hair loss reduction concerns the hair shedding from the follicles.
The increase in the diameter of the stem applies to the dimensions of the existing hair.
The change in the proportions of thick and thin hair affects the diameter distribution.
An increase in density means an increase in the number of visible hairs on a specific area of the scalp.
The improvement in the appearance in photographs, however, can result from several such changes at the same time.
Each of these effects may be significant, but each requires evidence appropriate to the specific declaration.
Preclinical studies involving cells, isolated human stem cells, and animal models can provide valuable information regarding biological plausibility and potential mechanisms. However, they should not be directly translated into claims regarding clinical efficacy.
Available studies in humans also show another important limitation: some of the publications concern specific lotions or multi-component formulations, rather than isolated peptides.
Positive results from such products support further research into the specific formulation, but do not automatically indicate that one peptide is the cause of the observed effect.
Stronger evidence would require larger, appropriately controlled and transparent human studies that precisely define the diagnosis, characterize the intervention being studied, apply appropriate comparison groups, and present both absolute and relative changes.
Longer observation would help determine whether the observed improvement persists, reaches a plateau, or disappears after discontinuation of use.
An independent replication of the results would be particularly valuable, allowing to determine whether the early positive observations can be reproduced outside the original research environment.
At the current stage, a scientifically substantiated claim does not therefore mean either „peptides work” or „peptides do not work” on hair loss.
Individual interventions involving peptides have varying levels of evidence, and each claim must be evaluated based on the specific experiment that supports it.
Disclaimer
The article is purely educational and scientifically informative. It discusses research on peptides in the context of hair loss and explains how to interpret clinical and preclinical evidence. It does not diagnose the causes of hair loss, does not recommend medications or cosmetic products, does not provide instructions for using peptides, and does not state that any peptide formulation is suitable for a specific individual.
Hair thinning, increased hair loss and visible hair loss can have various, sometimes overlapping causes. Results regarding a single diagnosis, a single peptide sequence, a single experimental model, or a single ready-made formulation should not be automatically transferred to other conditions or products.
Laboratory test results in cell cultures, isolated human tissues, or animal models may support biological hypotheses, but in themselves they do not confirm clinical efficacy or safety in humans. Similarly, results from a small or short-term study in humans do not guarantee long-term efficacy, the absence of rare adverse effects, or usefulness in other populations.
Unexplained, sudden, persistent or progressive hair loss may require appropriate clinical evaluation to determine the cause. Evidence regarding products containing peptides should be interpreted in accordance with the specific compound, formulation, population, comparator group and endpoint that were actually the subject of the study.
References
- American Academy of Dermatology Association. (n.d.). Hair loss: Diagnosis and treatment. Retrieved September 25, 2026, from https://www.aad.org/public/diseases/hair-loss/treatment/diagnosis-treat
- Pyo, H. K., Yoo, H. G., Won, C. H., Lee, S. H., Kang, Y. J., Eun, H. C., Cho, K. H., & Kim, K. H. (2007). The effect of tripeptide-copper complex on human hair growth in vitro. Archives of Pharmacal Research, 30(7), 834–839. https://doi.org/10.1007/BF02978833
- Iwabuchi, T., Takeda, S., Yamanishi, H., Ideta, R., Ehama, R., Tsuruda, A., Shibata, H., Ito, T., Komatsu, N., Terai, K., & Oka, S. (2016). The topical penta-peptide Gly-Pro-Ile-Gly-Ser increases the proportion of thick hair in Japanese men with androgenetic alopecia. Journal of Cosmetic Dermatology, 15(2), 176–184. https://doi.org/10.1111/jocd.12216
- Li, X., Wang, X., Wang, C., Zhang, J., & Zhou, C. (2022). Evaluation of hair shedding in alopecia: A refined wash test. Clinical, Cosmetic and Investigational Dermatology, 15, 117–126. https://doi.org/10.2147/CCID.S347898
- American Academy of Dermatology Association. (n.d.). Hair loss: Who gets it and what causes it. Retrieved September 25, 2026, from https://www.aad.org/public/diseases/hair-loss/causes/18-causes
- Ohn, J., Been, K. W., Kim, J. Y., Kim, E. J., Park, T., Yoon, H. J., Ji, J. S., Okada-Iwabu, M., Iwabu, M., Yamauchi, T., Kim, Y. K., Seok, C., Kwon, O., Kim, K. H., Lee, H. H., & Chung, J. H. (2021). Discovery of a transdermally deliverable pentapeptide for activating AdipoR1 to promote hair growth. EMBO Molecular Medicine, 13(10), Article e13790. https://doi.org/10.15252/emmm.202013790
- Kim, S., Kim, J. Y., Leem, J. W., Jo, H. J., Leem, J. W., Kang, H. Y., Han, E. H., Lee, B. G., Jiang, H. H., Roh, E., & Jung, S. K. (2026). Hydrolyzed keratin peptide enhances hair condition and promotes hair regeneration. Journal of Medicinal Food, 29(9), 555–566. https://doi.org/10.1177/1096620X261453142
- Lueangarun, S., & Panchaprateep, R. (2020). A combination of herbal extracts (biochanin A, acetyl tetrapeptide-3, and ginseng extracts) versus 3% minoxidil solution for the treatment of androgenetic alopecia: A 24-week, prospective, randomized, triple-blind, controlled trial. Journal of Clinical and Aesthetic Dermatology, 13(10), 32–37. https://pubmed.ncbi.nlm.nih.gov/33584955/
- Rinaldi, F., Marzani, B., Pinto, D., & Sorbellini, E. (2019). Randomized controlled trial on a PRP-like cosmetic, biomimetic peptides based, for the treatment of alopecia areata. Journal of Dermatological Treatment, 30(6), 588–593. https://doi.org/10.1080/09546634.2018.1544405